New CAR-T therapy shows promise for lymphoma patients who relapsed after prior treatment

NCT ID NCT04316624

Completed Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new cell therapy called C-CAR066 in 7 people with diffuse large B-cell lymphoma whose cancer had returned after CD19 CAR-T treatment. The therapy uses the patient's own immune cells, modified to target a different protein (CD20) on cancer cells. The main goals were to check safety and see if the treatment could shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: C-CAR066 (a type of CAR-T cell therapy that targets CD20 on cancer cells)
What this could lead to: If successful, this could offer a new treatment option for people with diffuse large B-cell lymphoma whose cancer returned after CD19 CAR-T therapy.
What could go wrong: This is a very early, small Phase 1 trial with only 7 participants, so results may not apply widely. CAR-T therapies can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital

Tianjin, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.